Jakafi® (ruxolitinib) – New orphan indication
May 24, 2019 - Incyte announced the FDA approval of Jakafi (ruxolitinib), for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
Download PDF
